title: Flecainide - Neonatal Intensive Care Drug Manual
text: |
  Neonatal Intensive Care Drug Manual
  |
  bet | 207/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Flecainide
  Revision Date : 12-01-2021
  |
  Approved : TC, KOH
  |
  Alert
  |
  Use in consultation with a Paediatric Cardiologist.
  Contraindicated in infants with reduced myocardial contractility.
  Use caution in patients with congenital heart disease—increased potential for pro-arrhythmic effects.
  Intravenous flecainide needs close cardiorespiratory monitoring
  |
  Indication
  |
  Treatment of paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation/flutter and life- threatening ventricular dysrhythmias as a second-line agent where tachycardia has been resistant to first-line agents.
  |
  Action
  |
  Decreases intracardiac conduction for all parts of the heart, with the greatest effect in the His-Purkinje system. It acts by blocking fast sodium channels. As a type Ic agent, it slows cardiac conduction and decreases contractility.
  |
  Drug type
  |
  Type Ic antiarrhythmic agent.
  |
  Trade name
  |
  Flecainide Sandoz Tablets; Flecatab Tablets; Tambocor solution for injection, Tambocor Tablets
  |
  |
  |
  | |